Forensic Analysis · General / Diversified · as of Jun 28, 2026
ESCALADE INC (ESCA)
A forensic read on ESCALADE INC built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
9.7
Altman Z-score
Clean
Earnings quality
3
Forensic signals
17.2
P / E (ttm)
9.0%
ROE
$266M
Market cap
3.31%
Dividend yield
ESCALADE INC earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is 9.7, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
7%Return on invested capital.Return on invested capital is 7% and steady — around its ~9% cost of capital, so growth is roughly value-neutral — watch the trend.
+0.4%/yrShare-count dilution.Diluted share count changed +1% over the last 3 years to FY2025 (+0.4%/yr). Roughly flat — buybacks are about offsetting stock comp, not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.
-24%Dividend — cut.The payout was CUT ~24% in FY2023 (from FY2022). It still returns some cash, but it is NOT the dependable, rising dividend an unbroken streak implies — weigh the cut when judging reliability.
Key fundamentals
Net Margin5.7%
Debt / Equity0.11x
Free Cash Flow$28.5M
Latest Revenue$240.2M
Return on Equity7.9%
Revenue Growth YoY-4.5%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on ESCALADE INC:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about ESCA's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown